A feasibility study of a Family Focused Treatment for Adolescents with Bipolar Disorder—the FAB study by Joanne Neely et al.
STUDY PROTOCOL Open Access
A feasibility study of a Family Focused
Treatment for Adolescents with Bipolar
Disorder—the FAB study
Joanne Neely1, David Miklowitz2, Ann Le Couteur3, Vicky Ryan3, Luke Vale3, Ruth McGovern3 and Aditya Sharma1,4*
Abstract
Background: The aim of this study is to examine the feasibility of a future definitive randomised controlled trial of
Family Focused Treatment for Adolescents UK (FFT-A UK) in the management of early-onset bipolar disorder (EOBD)
(under 18 years). The FFT-A has been evaluated in the USA to augment the pharmacological treatment of
adolescents with bipolar disorder (BD). The FFT-A UK has been condensed to 16 sessions over approximately
6 months to be utilised within the UK National Health Service.
Research from the USA suggests that families experience high levels of distress, stress, burden and family
disharmony when living with a young person who has BD. The FFT-A UK is a family-based approach
designed to increase understanding of BD (psycho-education), improve communication and increase ability to
problem-solve.
Methods/Design: The trial will examine the feasibility of a randomised, parallel group, non-blinded design and
the procedures of a subsequent definitive trial. Thirty-three young people with BD and their families will be
recruited. Participants will complete measures at baseline, on completion of the 6-month treatment and again
after a further 6 months. The self-report measures include the Warwick Edinburgh Mental Well-being Scale,
The McMaster Family Assessment Device (FAD), Conflict Behaviour Questionnaire aka ‘Interaction Behaviour
Questionnaire’, EuroQuol EQ-5D-3L and EQ-5D-Y. Primary outcomes will be rates of eligibility, recruitment and
retention, estimates of the variability in the self-report measures and assessment of the intervention delivery
in the study population. Participants’ qualitative views on the measures and intervention will be sought to
confirm the acceptability of intervention and study design. The health economics component will establish
how cost-effectiveness will be assessed in a future definitive trial.
Discussion: The study will produce a full trial protocol and amendments to the FFT-A UK to inform a well-designed
multi-centre randomised controlled trial (RCT) as an adjunct to pharmacotherapy in the management of EOBD.
Trial registration: Current Controlled Trials ISRCTN59769322
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Background
Bipolar disorder (BD) is a chronic remitting and relaps-
ing mood disorder, characterised by mood swings from
‘lows’ (depression) to ‘highs’ (mania/hypomania) with
periods of relative stability in between. It is most fre-
quently diagnosed in young adults (20–30 years), but
recent research has shown that the onset of symptoms
can occur earlier. Early-onset BD (EOBD) often co-oc-
curs with other mental health and developmental dis-
orders making the diagnosis and management more
difficult [1–3].
EOBD defined for this study as onset before 18 years
of age is associated with high rates of impairment in
emotional, cognitive and social development [4]. The
National Institute for Health and Clinical Excellence
(NICE) bipolar guidelines note that the involvement
of families is important in the management of young
people with EOBD and recommend psychological in-
terventions over 6 months in combination with psy-
chopharmacology [5].
There are a few evidence-based psychotherapeutic
treatment options for EOBD. A number of psycho-
logical treatments used with adults with BD have
been adapted for use with affected adolescents.
These include Interpersonal and Social Rhythm
Therapy [6], Dialectical Behavioural Therapy [7] and
Cognitive Behavioural Therapy (CBT) [8, 9]. These
treatments have been effective in research done in
the USA and have shown to delay the recurrence of
episodes, stabilise symptoms and improve medication
adherence. Other researchers have tailored therapy
to include the family in conjunction with the young
person. This research has shown that family-focused
CBT is effective in treating children aged between 7
and 13 years with BD [10]. Furthermore, recent re-
search has suggested that reducing parent stress and
improving family functioning may be the most po-
tent ingredient of the treatment [11]. Fristad and col-
leagues [12] have shown that a multi-family psycho-
education group method is effective in improving
symptoms and social and family functioning. Miklo-
witz et al. have adapted their manual-based family
treatment for adults for use with adolescents (FFT-A)
[13]. The results of a 2-year randomised controlled
trial showed that those adolescents who received the 9-
month, 21-session intervention had a more favourable
and rapid recovery from their index depressive episode
than patients in enhanced care (mean 10.2 weeks, 95 %
CI 1.04–3.29, p = 0.04) [13]. A further study showed
that FFT-A had a stronger effect for those who live in
families with high emotional stress levels whereby ado-
lescents with BD in high expressed emotion families
showed greater reductions in both depressive and
manic symptoms [14]. A more recent study showed that
FFT-A together with pharmacotherapy proved no more
effective than pharmacotherapy with brief psychotherapy
in speeding up recovery or delaying recurrence of BD in
adolescents. However, FFT-A was more effective than
brief psychotherapy in reducing the severity of manic
symptoms in year 2 [F(8,742) = 1.98, p = 0.046] [15].
BD affects not only the patient but also their family.
Family-based interventions may therefore offer advan-
tages in the long-term management of this disorder.
One study has reported that there are high levels of
stress in parents of youths with BD [16]. Reinares and
colleagues [17] showed that a psycho-education family
intervention reduced the distress and subjective burden
and the caregiver’s belief about the link between the ob-
jective burden and the patient. Other studies in families
with BD children acknowledged significantly more
minor conflicts with family members than either uni-
polar or control group families [18]. Belardinelli et al.
[19] found that the family environment of bipolar
children in comparison to healthy children showed
greater levels of dysfunction as measured by the Family
Environment Scales. Parents of children with BD re-
ported lower levels of family cohesion (p < 0.001), ex-
pressiveness (p = 0.005), active-recreational orientation
(p < 0.001), intellectual-cultural orientation (p = 0.04)
and higher levels of conflict (p < 0.001) than parents with
no bipolar children. Furthermore, a study reported
higher levels of conflict (z=4.729, p < 0.0001) on the
Family Environment Scales in families where one parent
had BD than families where neither parent has BD [20].
That family functioning is important in the prognostic
outcome of EOBD has been demonstrated in a study
that showed decreased family problem solving ability, as
measured by the Family Assessment Device (FAD), pre-
dicted increased persistence of adolescents’ depressive
symptoms [21]. The psychotherapeutic studies for EOBD
to date have been undertaken in the USA. Given the dif-
ferences in the health care systems between the USA
and the UK, it is important to evaluate the effectiveness
(including the cost-effectiveness) of psychotherapeutic
evaluations for EOBD in the UK. This study intends
to examine mental well-being and impact on family
functioning along with quality of life adjusted years
(QALYs).
Aim
The aim of this study is to examine the feasibility of
a future randomised controlled trial (RCT) of family-
focused treatment (FFT-A UK) in the management of
EOBD. The FFT-A was first adapted from the FFT in
the USA to treat young people with BD and their
families. The FFT-A UK version is further adapted
from the original. These adaptations include some
textual changes to make the version more relevant to
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UK culture (e.g. Coach replaced with Therapist) along
with being condensed into 16 sessions taking place over
6 months (as opposed to the existing FFT-A version at the
time of 21 sessions taking place over 9 months).
The study will investigate the acceptability of the
FFT-A UK and explore issues of eligibility, random-
isation, recruitment and retention rates and variabil-
ity in the proposed outcome measures to inform the
design of a multi-centre RCT with long-term follow-
up.
The specific objectives of this feasibility trial are:
1. Is it feasible to deliver the FFT-A UK to young
people (under 18 years) and their families?
2. What are the likely consent, eligibility and retention
rates as well as the acceptability of being randomised
to a delayed treatment arm?
3. What are service users and their family’s views about
taking part in a RCT and completing the study
assessments and outcome measures?
4. What is the variability in the outcome measures?
The results of this feasibility study will inform the de-
velopment of a definitive multi-centre RCT to evaluate
the clinical and cost-effectiveness of FFT-A UK as an ad-
junct to pharmacotherapy in the management of EOBD.
Our hypothesis for the definitive RCT will be that the
addition of a family-focused psycho-educational treat-
ment will be more effective and cost-effective in the
management of EOBD than treatment as usual (TAU)




The feasibility trial of a modified version of the FFT-
A will examine the design and procedures for a sub-
sequent definitive trial of the FFT-A UK for use in
UK community-based settings. This is a mixed
methods feasibility study with two components:
1. A single-centre, open randomised controlled trial
of FFT-A UK in the management of EOBD com-
pared to treatment as usual. The primary out-
come
measures are rates of recruitment, randomisation
and data completion. We will also investigate
the variability in the validated questionnaires to
determine the best measures to use in a future
definitive trial.
2. Qualitative interviews of a purposively
sampled sub-set of families eligible for the
feasibility trial to explore willingness to
participate, be
randomised and explore overall trial experience.
An attempt will be made to undertake qualitative
assessments with families who did not consent to
be randomised.
Participants
Thirty-three (to allow for a 10 % attrition rate) young
people with a clinical diagnosis of EOBD and their fam-
ilies will be recruited into this trial.
Inclusion criteria
1. Confirmation of diagnosis of BD and currently in
remission using the WASH U KSADS
(Washington University at St. Louis Kiddie
Schedule for Affective Disorders and
Schizophrenia) [22]
2. Fluent in the English language
3. Typically developing with ability in the average
range and able to engage in psychotherapy (i.e.
attending or having attended mainstream school)
4. Age between 11 and 18 years
Exclusion criteria
1. Not meeting criteria for a diagnosis of BD according
to the WASH U KSADS
2. Currently unwell in an episode of bipolar disorder
(e.g. mania/hypomania/depression/mixed episode)
3. Lack of fluency in the English language that might
prevent engagement in psychotherapy
4. Low intellectual functioning that might not allow
young people to engage in the FFT-A UK
Recruitment
Referrals were made through:
1. The National Tertiary Adolescent Bipolar Service,
Northumberland Tyne and Wear NHS Foundation
Trust.
2. Consultant Child and Adolescent Psychiatrists
within Child and Adolescent Mental Health
Services (CAMHS) in North East England. With
the permission of the treating Consultant Child
and Adolescent Psychiatrist, a Clinical Studies
Officer (CSO) from the Clinical Research Network
(CRN) will search patient records electronically and
inform the clinician of potential participant families.
3. Advertising this study in the North East England
with Bipolar UK, via their newsletter, ‘Pendulum’.
Potential participants will be asked to contact
their clinically responsible Consultant Child and
Adolescent Psychiatrist to discuss the research
project.
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Consent component 1
The referring Consultant Psychiatrist will give the young
person and their family the Study Information Pack
(SIP). The SIP will consist of information sheets for
the young person, parents/carer and an Expression of
Interest (EOI) form. The clinician will ask the family if
he/she can forward their contact details to the research
team so that they can ask more questions about the
study before making a decision about giving written in-
formed consent. Alternatively, using the contact infor-
mation (email, telephone and/or post) on the EOI form,
the research team can contact the young people and
their families directly. Potential participants will be
given at least 48 h to read the information sheets before
the consent visit will take place. The research team will
then request a CSO from the North East and North
Cumbria CRN to set up a mutually convenient time and
venue to meet with the young person and his/her family
to further discuss this project in detail. Those wishing
to take part are asked to provide written informed con-
sent by initialling, signing and dating a study consent
form which is witnessed by the CSO who has docu-
mented delegated responsibility to do so. Written in-
formed consent is always obtained before any study-
specific procedures including eligibility assessments and
the collection of baseline data take place. Informed con-
sent and assent are taken as appropriate. The original
signed consent/assent forms are retained in the investi-
gator site file with a copy retained in the clinical notes
and another copy provided to the participant and family.
Those families who decline to take part will be asked if
they would like to give their reasons, though the right to
refuse to participate without giving reasons is respected.
After consent and assent, the eligibility assessments will
be undertaken during a separate appointment.
Consent component 2—qualitative interviews
Upon completion of the FFT-A UK, patients and their
families will be invited to take part in the qualitative part
of the study. They will be asked to comment about the
treatment programme, fill out questionnaires, be rando-
mised, etc. Information sheets will be given to families at
the end of the final treatment session. After a minimum
of 48 h, the research team will then request a CSO from
the North East and North Cumbria CRN to set up a mu-
tually convenient time and venue to meet with the
young person and his/her family to further discuss this
aspect of the project in detail. Those wishing to take part
are asked to provide written informed consent by initial-
ling, signing and dating a study consent form, which is
witnessed by the CSO who has documented delegated
responsibility to do so. Those consenting will be con-
tacted by a member of the research team to discuss a
suitable date, time and venue for the interview.
Eligibility
Eligibility will be assessed using the WASH U KSADS
[22]. This is a reliable and valid interview schedule used
in research to confirm diagnosis and is carried out with
the young person and his/her parent/carer. This eligibil-
ity assessment takes about 2–3 h to complete. Young
people may participate if they meet the eligibility criteria
and either are euthymic or have sub-threshold symp-
toms of an affective episode provided they are able to
consent.
Outcome measures
Most of the research studies on interventions in EOBD
have focused their primary outcomes on clinical parame-
ters such as symptomatic improvement, frequency of
mood episodes and/or their duration, less need for hos-
pitalisation or longer time spent in remission. Few stud-
ies have attempted to evaluate the intervention in terms
of improvement in family functioning and/or health-
related quality of life (HRQL). This mode of enquiry
adopts a more patient-centred approach that focuses on
the individuals’ perceptions of their physical, psycho-
logical and social functioning. An Australian study
showed that children with mental health disorders were
reported to have a worse HRQL than children with
physical disorders and their problems interfered sig-
nificantly with the daily lives of children, parents and
family [23].
Validated quantitative questionnaires
The McMaster Family Assessment Device (FAD) [24]
The FAD is a 60-item, 4-point Likert-type questionnaire
designed to evaluate families according to the McMaster
Model of Family Functioning. It takes approximately
15 min to complete. It is made up of 6 scales which
measure problem solving, communication, roles, affective
responsiveness, affective involvement and behaviour con-
trol. In addition, there is a 12-item measure of general
functioning that can be used as a global measure of family
health/pathology [25]. It has good psychometric properties
with good reliability and validity [26–28].
There are low correlations between FAD and the
Marlowe-Crowne Social Desirability test, suggesting that
the FAD responses are relatively free of the influence
of social desirability [26]. This will be completed by
parent/s.
Conflict Behaviour Questionnaire (CBQ) aka
‘Interaction Behaviour Questionnaire’ [29] The
CBQ is a self-report measure of problems with interper-
sonal behaviour between dyads (e.g. the mother about
the adolescent or the adolescent about the father). Re-
spondents answer true or false to questions about their
relationship with a particular family member. The short
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form has 44 items and correlates 0.96 with the long ver-
sion. It has been widely used [30, 31] and has adequate
internal consistency and discriminant validity [29]. Both
young people and one parent will complete this.
EuroQuol EQ-5D and EQ-5D-Y EQ-5D is a standar-
dised instrument for use as a measure of health
outcome. The EQ-5D-Y is a youth version. It is develop-
mentally appropriate and takes only a few minutes to
complete. This will be completed by a young person and
a parent. The EQ-5D descriptive system comprises 5
dimensions: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each dimension
has 3 levels: no problems, some problems, extreme
problems. The EQ-5D-Y has the same basic system
with some changes in wording. The EQ-5D is scored
using UK population tariffs (a scoring system is under
development for the EQ-5D-Y), which can be used in
the calculation of quality adjusted life years (QALYs).
QALYs are commonly used in economic evaluations.
Warwick Edinburgh Mental Well-being Scale
(WEMWBS) [32] This scale has been developed by
Warwick and Edinburgh Universities to assess mental
well-being. WEMWBS is a 14-item scale with 5 response
categories, summed to provide a single score ranging
from 14 to 70. The items are all worded positively and
cover both feeling and functioning aspects of mental
well-being. Its psychometric properties are robust and it
is easy to complete [33]. This will be completed by the
young person.
Self-completed baseline questionnaires will be given to
the young person (3 in total, completion time, 30 min)
and his/her family (3 for primary caregiver, completion
time approx. 30 min), and an appointment for the re-
search associate to collect these will be arranged. Assist-
ance, via the CSO, will be offered to those who have
difficulty filling them in. Once the questionnaires have
been completed and returned, the randomisation pro-
cedure will occur. Randomisation will occur after base-
line questionnaire completion as we do not want the
type of treatment group allocation to bias questionnaire
responses. Participants will be given a voucher (‘love to
shop’) for £10 on completion of each batch of ques-
tionnaires (£30 in total). Participants and their fam-
ilies will complete these sets of questionnaires on 3
separate occasions, before randomisation, after treat-
ment (at 6 months) and again after 12 months follow-
ing randomisation.
Randomisation
Participants will be randomised to ‘immediate treatment
arm’ or ‘delayed treatment arm’ in a 1:1 ratio, using ran-
dom permuted blocks. The randomisation allocation
schedule will be generated by a statistician with no other
involvement in the study. Randomisation will be per-
formed by a trained member of the research team or
CSO, using a secure password-protected Web-based sys-
tem administered by Newcastle Clinical Trials Unit
(https://apps.ncl.ac.uk/random). Randomisation will
generate a unique 2-digit ‘study ID number’ for each
participant.
Interventions
Control condition: delayed treatment with treatment
as usual
Families and the young person with bipolar disorder will
receive usual care delivered by their referring Consultant
Child and Adolescent Psychiatrist and the CAMHS team
(usually a review appointment every 3–6 months). Fam-
ilies and young people will be offered the intervention
after 1 year when all trial data collection is completed.
Intervention condition: immediate treatment
All family members living at home or involved in the
care of the young person will be invited to attend the
treatment and will receive 16 sessions of 1-h duration
with a therapist over 25 weeks (1 therapist, 1 family
unit). Treatment will be suspended if the young person
becomes unwell as declared to the research team or
Therapist by their referring Clinician.
The treatment structure includes:
1. Seven weekly psycho-education sessions. During
these sessions, the family and young person will be
given information about the aetiology, treatment and
self-management of BD. A relapse prevention plan
and identifying early prodromal signs to lessen the
impact and possible need for hospitalisation will be
considered.
2. Four fortnightly communication enhancement
sessions will teach young people and their parents
communication skills, offer positive feedback and
active listening, make positive requests for change in
others’ behaviour and give negative feedback.
3. Four fortnightly problem solving skill training
sessions encourage an open dialogue between family
members about difficult topics and help all involved
to develop strategies for solving these problems.
4. A final overview session completes the intervention.
Participants will complete validated questionnaires, at
baseline, immediately post intervention and again at
follow-up after 6 months (T0, T6 and T12 months).
Treatment may take longer than 6 months if the
young person becomes unwell. They will continue to get
their therapy when they recover from an episode. If the
T6 and T12 questionnaires are delayed by more than
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6 months from the dates when they were meant to be
completed, this will be considered as missing data. The
young person and his/her family will be considered as a
‘dropout’ if he/she tells the research team that he/she no
longer wishes to continue.
Families will be contacted by the research team on a
monthly basis via text or email throughout the trial to
be kept updated and to maintain good retention rates.
On completion of the research study, young people
will receive a certificate thanking them for their
participation.
Training
All therapists will have undergone a 1-day workshop
(9 am–5 pm) with Professor David Miklowitz, the author
of the Family Focused Treatment—Adolescent (FFT-A).
Each therapy session will be video-recorded, and 25 % of
these will be viewed by David Miklowitz to ensure fidel-
ity, using the Therapist Competence and Adherence
Scale [34]. Therapists are given fortnightly supervision
by AS, provided with written feedback and Skype super-
vision every 2 months by David Miklowitz.
Participant compliance
Where feasible, appointments will be arranged at the
participants’ convenience at a NHS venue of their choice.
Therapists will arrange clinical appointments and record
which family members attend each session. Should a
participant become unwell during the study, his/her
intervention will be ‘suspended’ and he/she will re-
sume therapy when he/she is well enough to partici-
pate in the FFT-A UK as determined by their treating
clinician. The primary outcomes for this feasibility
trial are rates of eligibility, recruitment, intervention
delivery and participant retention at follow-up. These
will be recorded on case report forms by the Trial
Coordinator.
Economic evaluation
A review of the existing health economics databases will
be conducted to identify possible alternative measures of
health state utility with young people with EOBD and
their families. The search will be conducted in the two
major health economic evaluation databases: NHS
Economic Evaluation Database (NHS EED) and the
Cost-Effectiveness Analysis Registry. NHS EED includes
structured abstracts of quality-assessed full economic
evaluations of health care technologies, with the only
criterion for inclusion in the database is that the study is
a full economic evaluation. The economic evaluations
are selected as a result of hand searching journals, health
technology assessment reports and electronic searches
of CINAHL, Embase, MEDLINE and PsycINFO. Ab-
stracts are prepared based upon the potential relevance
of the study to the United Kingdom National Health
Service (UK NHS), which is important as all health-
related quality of life outcomes for this study should
ideally have been used in the UK NHS setting (or a
closely comparable alternative).
Additionally, this review will also use the Cost-
Effectiveness Analysis Registry. This registry focuses on
a particular type of economic evaluation—a cost utility
analysis. This form of analysis requires measures of
health-related quality of life, so it may be applicable to
our review.
As a result of the review, we hope to identify the
following:
1. What tools have been used to gather health utility
data in similar settings?
2. Where were these tools used and are they potentially
suitable for use in a multi-centre definitive trial?
3. Key references from other researchers in the field if
applicable to a UK NHS setting.
Sample size considerations
No formal sample size calculation has been performed
for this feasibility study as the primary outcome mea-
sures are concerned with the recruitment and random-
isation to the trial and the acceptability of the trial in
this population of patients. However, a sample size of
n = 30 patients will provide sufficient data [35] to esti-
mate the variability in the outcome measures at base-
line and assess the feasibility of the trial. Data from a
recent similar RfPB-funded study, ‘Beating Anxiety
Together’ project from the NE of England [36], indicates
that two thirds of families approached consented to taking
part in the research and that attrition during the therapy
phase was less than 10 %. Therefore, in order to achieve
30 participants who complete the trial and provide follow-
up data, it may be necessary to approach 50 patients.
Quantitative data and analysis
A database will be designed to facilitate accurate data
entry with inbuilt checks, and a proportion of the data
entry will be checked. As this is a feasibility study, the ana-
lyses of the data collected will be mainly descriptive, with
95 % confidence intervals reported where appropriate.
At baseline, the distribution of all numerical variables
will be examined graphically and summarised by appro-
priate measures of location and spread. Similarly,
baseline categorical variables will be tabulated and per-
centages reported. No formal statistical comparisons be-
tween treatment arms will be made; any comparisons
will be descriptive and exploratory. Confidence limits for
the estimated standard deviations of key study parame-
ters will be calculated and used in sensitivity analyses for
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sample size calculations for a future multi-centre RCT
study application.
Qualitative data and analysis
Semi-structured interviews with young people and fam-
ily members in the trial will be employed to gather their
individual views in detail, while a focus group will allow
trial participants to feed back on the findings from the
individual interviews, and provide socially constructed
perspectives to contrast with individual ones. Employing
both methods will enable the participation of both those
who may feel inhibited by group discussion and those
unable or unwilling to attend interviews.
We will purposively sample families (n = 15), including
three families in the control condition, seeking a repre-
sentative male/female ratio and diversity in terms of age,
diagnosis and time since diagnosis, family members and
size. An attempt will be made to interview 2 family
members within each family either face to face at the
University, at home or by telephone by a qualitative re-
searcher, giving a sample of 30 participants. Interviews
will commence after 6 months following the last session
of the intervention, with each interview expected to last
approximately 45 min. Since it will also be important to
feasibility to know why families may not wish to take
part in the intervention or research, we will also invite a
Fig. 1 Study protocol flowchart
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member from each of 5 families refusing participation to
consent to a brief telephone interview on a voluntary
basis to raise concerns they may have had. The interview
agendas will initially be developed by members of the
Project Advisory Group (PAG) including our parent and
young people representatives to cover areas of research
interest (attitudes towards and experiences of both the
intervention and research procedures). The agenda will
be flexible to allow both expected and emergent themes
to be incorporated into later interviews [37].
Both interviewees and family members who were not
interviewed will be invited to a focus group intended to
provide feedback on the initial findings and gain the
families’ perspectives on the outcomes of analysis. The
focus group discussion will be structured around a
presentation of the initial findings, thus allowing both
interviewees and non-interviewees with comparable cir-
cumstances to comment on how these represent the ex-
perience and attitudes of families affected by BD in
general and increase confidence in the broader applic-
ability of findings [38]. Interviews and the focus group
will be tape-recorded, with participant’s written consent,
transcribed, anonymised and subjected to framework
analysis [39]. This is an appropriate approach for quali-
tative health research with objectives linked to quantita-
tive investigation [40]. We will use NVivo to aid
indexing and charting. The data will be repeatedly read
and coded independently by two researchers to increase
the reliability of the study. When discrepancies between
coders exist, these will be discussed until a consensus is
reached. Analysis will be discussed at regular meetings
of the research team in order to identify areas for closer
consideration (including negative case analysis) and to
enhance credibility of the thematic framework and inter-
pretation [38]. Figure 1 shows a flow diagram from the
feasibility study.
Ethical and research governance approval
The study has been granted a favourable ethical opinion by
Sunderland NHS Research Ethics Committee (13/NE/0117).
Project timetable
The trial duration is 36 months. Recruitment commenced
on 15th January 2015 and is ongoing.
Discussion
Findings from this feasibility study will indicate whether
and how a definitive trial can establish the effectiveness
and cost-effectiveness of a family-focused treatment in
the management of EOBD. The outcomes will include
the protocol for such a trial, with a sample size calcula-
tion, which can usefully enhance the evidence base for
psychological interventions in the treatment of EOBD.
To the best of our knowledge, there are no trials in the
UK to support evidence-based decisions for psychological
treatments in the management of EOBD. The FFT-A has
been developed in the USA by David Miklowitz, as a
9-month, 21-session psychological treatment. This
study has condensed the sessions to 16 over a period
of 6 months to try to ensure its applicability and accept-
ance to the NHS. It could be that the intervention requires
further amendments or alterations. Findings from this
study will determine if this is required.
Despite recommendations from NICE about involving
families in the management of EOBD, there are no
UK-based studies to inform the delivery of effective
evidence-based interventions for the treatment of
young people with EOBD and their families. This
intervention, the FFT-A UK, is expected to improve
family functioning and benefit HRQL. It is also ex-
pected to lessen the impact and severity of further
episodes through teaching young people and their
family’s skills to self-manage their chronic condition.
Patient empowerment through self-management in a
collaborative partnership is important for patient
health and well-being [41, 42]. This project should
heighten awareness amongst clinicians about the dis-
order which will encourage better recognition, earlier
diagnosis and intervention (though not directly assessed
in this trial). This in turn should improve the prognosis of
EOBD by delaying and reducing the severity of relapse ep-
isodes and cutting costs in the longer term.
We plan to proceed to a full multi-centre RCT to deter-
mine the clinical effectiveness and cost-effectiveness of
this intervention. If effective and cost-effective, we would
hope that in keeping with NICE guidelines, the FFT-A UK
will be an integral part of the assessment and management
pathway for young people with bipolar disorder.
Trial status
The trial is currently recruiting.
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